en.Wedoany.com Reported - Asahi Kasei Life Science announced a technology licensing and collaboration agreement with the Noguchi Institute to jointly develop a novel antibody-drug conjugate (ADC) technology with enhanced precision and uniformity. This technology enables precise control of the drug-to-antibody ratio and the attachment sites for both single-load and dual-load ADCs.
ADCs represent an advanced targeted biotherapeutic approach, combining the precision of antibodies with the potency of cell-killing payloads. Compared to conventional therapies, the bioconjugation of ADCs allows for more selective targeting of cancer cells while minimizing damage to surrounding normal cells. Leveraging the Noguchi Institute's long-standing expertise in carbohydrates and glycans, the institute has developed a novel ADC technology with superior molecular structural consistency, which is expected to improve the predictability of drug efficacy and safety, thereby achieving stable therapeutic outcomes.
Asahi Kasei Life Science continues to explore collaboration opportunities with external partners, seeking cutting-edge technologies that can lead future drug development. The Noguchi Institute's ADC technology not only enhances precision but also enables the combination of dual payloads onto a single antibody. These characteristics empower the drug with the ability to incorporate different payloads, thereby targeting more diseases with better specificity and potentially lower toxicity.
Under this agreement, both parties will jointly advance the commercialization plan for the ADC drug platform, including potential future sublicensing to biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) such as Asahi Kasei's Bionova Scientific. Additionally, they will conduct collaborative research to further refine the technology to address challenges in the medical field.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
